Calcium acetate
Brand names: Phosex, Renacet
Calcium acetate is an oral calcium-based phosphate binder used to control hyperphosphataemia in chronic kidney disease, particularly in patients on dialysis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Taken with food, it binds dietary phosphate in the gut to form insoluble, non-absorbed calcium phosphate, reducing phosphate absorption and lowering serum phosphate.
Prescribing in practice
- It must be taken with meals to bind dietary phosphate; the principal risk is hypercalcaemia, so the overall calcium load must be limited to avoid vascular calcification.
- Avoid in hypercalcaemia and use cautiously where calcium intake from all sources is already high, switching to a non-calcium binder if hypercalcaemia develops.
- Separate administration from oral medicines whose absorption it reduces, including certain antibiotics, iron, levothyroxine and bisphosphonates.
Monitoring
Monitor serum calcium and phosphate regularly to maintain phosphate control while avoiding hypercalcaemia.
Counselling the patient
- Take it with or just before food so it can soak up the phosphate in your meal.
- Keep separate from other tablets such as some antibiotics, iron and thyroid medicine.
- Report symptoms of a high calcium level such as nausea, constipation or confusion.
Evidence & guidelines
Phosphate binder use and calcium-balance considerations in CKD are guided by KDIGO and NICE CKD mineral and bone disorder recommendations.
Reference: NICE NG203; KDIGO CKD-MBD; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- HIV Opportunistic Infection Risk (CD4-Based) · HIV / Immunodeficiency
- Corrected Calcium · Electrolytes
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019